Other Knowledge Centres
ADHD
Alzheimer's Disease
Arthritis
Asthma
Atopic Dermatitis
Cholesterol
Chronic Myeloid Leukemia
COPD
Cystic Fibrosis
Diabetes
Gastrointestinal Stromal Tumours
Hepatitis
Hypertension
Insomnia
Lysosomal Storage Disorders
Men's Health
Migraine
Multiple Sclerosis
Niemann-Pick
Non-small Cell Lung Cancer
Ophthalmics
Opioids and Pain
Osteoarthritis
Parkinson's Disease
Post-MI Heart Failure
Prostate Cancer
Renal Cell Carcinoma
Renal Anaemia
Soft Tissue Sarcoma
SGLT2-Inhibitors eCME Webcast
Disease Topics
Allergy and Clinical Immunology
Anesthesiology
Angiology
Cardiology
Central Nervous System
Clinical Laboratory
Complementary and Alternative Medicine
Critical Care/Intensive Care
Dermatology
Diabetes and Endocrinology
Ear, Nose and Throat
Emergency Medicine
Eye Health and Disorders
Family Medicine
Gastroenterology
Gerontology/Geriatrics
Haematology
Hepatology
HIV/AIDS
Immunology
Infectious Diseases
Internal Medicine
Kidney and Urological Diseases
Medical Genetics
Men's Health, Andrology and Urology
Musculoskeletal Disorders
Neonatal/Perinatal Medicine
Neurological Disorders
Nutrition and Dietetics
Oncology
Orthopaedics
Paediatrics
Pain Management
Palliative Medicine
Plastic Surgery and Aesthetic Medicine
Podiatry
Preventive Medicine
Psychiatry/Mental Health
Radiology
Respiratory
Rheumatology
Sexual Health
Sleep Medicine
Sports Medicine
Surgery (General)
Transplantation
Tropical Medicine
Vaccines
Women's Health and Obs/Gyn
Back to EPG Online
EPG Diabetes Knowledge Centre
Home
The Need For Insulin Analogues
Treatment Overview
Treatment Options
IDF 2005
Further Reading
Treatment Options
Long term Action
Product
Levemir
®
Action Profile
Treatment Guidelines
Prescribing Information
PREDICTIVE™ Study
Benefits
Clinical Data
Suitable Devices
References
Dual Action
Short term Action
Treatment
Product benefits
Add Levemir
®
, reduce weight gain
A Initiate Levemir
®
once daily in type 2 diabetes
1,2,3
Read more
Less weight gain than NPH and insulin glargine
1,2,4
Read more
Effective HbA1c control
4,5
Read more
Low risk of hypoglycaemia
3,4,5
Read more